In view of the potential anti-tumor activity of tazemetostat against SMARCB1-deficient tumors, our institution is initiating a single-arm open-label phase II trial on induction chemotherapy TPF and tazemetostat, followed by either radical surgery and postoperative (chemo)radiation or radical concurrent chemoradiation and maintenance tazemetostat for locally advanced SMARCB1-deficient sinonasal carcinoma (NCT05151588) (Supplementary Figure S6) [61]. The gene discussed is SMARCB1; the disease is nasal cavity and paranasal sinus carcinoma.